SCHEMBL4517989

SCHEMBL4517989

Cc1cccc(C)c1OCC(C)NS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.59
CA2 P00918 5/20 0.44
MMP2 P08253 4/20 0.44
CA12 O43570 4/20 0.44
CA9 Q16790 4/20 0.44
CA14 Q9ULX7 3/20 0.44
CA1 P00915 3/20 0.44
MMP1 P03956 2/20 0.44
MMP9 P14780 2/20 0.44
MMP13 P45452 2/20 0.44
MMP3 P08254 1/20 0.44
MMP7 P09237 1/20 0.44
CA3 P07451 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA13 Q8N1Q1 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
SLC1A3 P43003 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4521826 0.90 NR3C1 (0.59) NR3C1CA2MMP2CA12CA9
SCHEMBL4515277 0.84 NR3C1 (0.63) NR3C1CA2MMP2CA12CA9
SCHEMBL4506870 0.82 NR3C1 (0.62) NR3C1MMP2CA12CA9CA14
SCHEMBL13889015 0.82 NR3C1 (0.62) NR3C1CA2MMP2CA12CA9
SCHEMBL4518136 0.81 NR3C1 (0.64) NR3C1CA2CA12CA9SLC1A2
SCHEMBL13889013 0.81 NR3C1 (0.59) NR3C1MMP2MMP1MMP9MMP13
SCHEMBL4503415 0.81 NR3C1 (0.59) NR3C1MMP2MMP1MMP9MMP13
SCHEMBL4516008 0.81 NR3C1 (0.59) NR3C1CA2MMP2CA12CA9
SCHEMBL4509097 0.81 NR3C1 (0.59) NR3C1MMP2MMP1MMP9MMP13
SCHEMBL4526843 0.81 NR3C1 (0.59) NR3C1CA2CA12CA9SCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
EP-1807391-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AstraZeneca AB (SE) 2007-07-18 EP disclosed
WO-2006046916-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 NR3C1 1/4885CA2 1356/4885MMP2 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.